Production (Stage)
Madrigal Pharmaceuticals, Inc.
MDGL
$278.23
$4.131.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.86% | -24.69% | -49.33% | -54.78% | -41.16% |
| Total Depreciation and Amortization | 138.70% | 107.97% | 70.23% | 42.40% | 17.98% |
| Total Amortization of Deferred Charges | -29.06% | -13.46% | 19.98% | 59.03% | 114.31% |
| Total Other Non-Cash Items | 37.89% | 59.81% | 78.28% | 86.89% | 64.94% |
| Change in Net Operating Assets | -1,217.35% | -2,108.33% | 952.56% | -210.48% | -135.68% |
| Cash from Operations | -1.54% | -40.51% | -42.34% | -62.10% | -50.31% |
| Capital Expenditure | 38.65% | 1.15% | -387.92% | -1,022.29% | -800.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.87% | 45.53% | -697.22% | -467.19% | -501.05% |
| Cash from Investing | 4.16% | 45.40% | -695.24% | -468.74% | -502.71% |
| Total Debt Issued | -- | -- | -100.00% | -70.00% | -64.71% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -84.35% | 38.57% | 279.55% | 284.34% | 284.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 73.96% | 86.35% |
| Cash from Financing | -84.77% | 23.52% | 214.91% | 235.41% | 204.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -185.20% | 102.20% | 6,368.84% | 1,665.60% | 616.93% |